Related Experiment Video
Updated: Jan 8, 2026
Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
Published on: May 31, 2024
Management and Treatment of Perianal Fistulizing Crohn's Disease
Joseph J Lee1,2,3,4, Amy L Lightner1,3,4
1Department of Colorectal Surgery, Scripps Clinic, La Jolla, CA, USA.
Insights
Perianal fistulizing Crohn's disease (PFCD) is a severe condition impacting quality of life. Mesenchymal stem cell (MSC) therapy shows promise for refractory PFCD, offering high remission rates with a good safety profile.
Area of Science:
- Gastroenterology
- Colorectal Surgery
- Regenerative Medicine
Background:
- Perianal fistulizing Crohn's disease (PFCD) is a severe phenotype affecting up to one-third of Crohn's patients.
- This condition significantly impairs quality of life due to pain, drainage, and risk of incontinence.
- PFCD indicates a more aggressive disease course requiring coordinated multidisciplinary care.
Purpose of the Study:
- To review the current management strategies for perianal fistulizing Crohn's disease.
- To highlight the role of multidisciplinary teams in optimizing patient outcomes.
- To discuss mesenchymal stem cell (MSC) therapy as a promising option for refractory cases.
Main Methods:
- Review of current medical and surgical management approaches for PFCD.
- Analysis of outcomes associated with conventional therapies.
- Evaluation of emerging treatments, including mesenchymal stem cell (MSC) therapy.
Main Results:
- Medical therapy achieves durable remission in only about one-third of patients.
- The majority of patients require surgical intervention, often with advanced disease.
- Mesenchymal stem cell (MSC) therapy demonstrates clinical remission rates of 50-80% with a favorable safety profile.
Conclusions:
- Optimal management of PFCD necessitates a multidisciplinary approach.
- Mesenchymal stem cell (MSC) therapy is a promising option for refractory PFCD, though no approved products are currently available.
- Individualized, evidence-based therapy is crucial for optimizing outcomes in complex PFCD cases.
Abstract:
Perianal fistulizing Crohn's disease is a severe and disabling phenotype of Crohn's disease, affecting up to one-third of Crohn's patients. This phenotype can result in significant quality of life impairment in quality of life due to chronic pain, persistent perianal drainage, and the risk of fecal incontinence. The presence of a perianal fistula indicates a more aggressive disease course, often requiring more frequent and coordinated care. Optimal management relies on a multidisciplinary team, including gastroenterologists, colorectal surgeons, and radiologists, to address the complex interplay of medical and surgical needs. Medical therapy achieves durable remission in only about one-third of patients, necessitating surgical intervention for the majority, with patients arriving to the operating room with more advanced disease activity and longer duration of immunosuppression. For patients with refractory disease, mesenchymal stem cell (MSC) therapy has emerged as a promising option, with clinical remission rates of approximately 50-80% at 6-12 months and a favorable safety profile, notably without increasing the risk of incontinence compared to conventional surgery. However, there is no approved MSC product currently available for clinical use. Given the complexity and morbidity of fistulizing perianal Crohn's disease, a multidisciplinary approach focused on individualized, evidence-based therapy is essential for optimizing outcomes.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...